Abstract 1531P
Background
Recent studies have demonstrated encouraging efficacy in patients with ESCC when combining PD-1 blockades with chemotherapy in the first-line setting. However, the safety profile of conventional chemotherapy remains unsatisfactory, suggesting the chemotherapy-free regimen a promising strategy. Anlotinib, a novel multitarget TKI primarily targeting VEGFR1-3, has shown therapeutic activity as first-line combination therapy or second-line monotherapy for ESCC patients in China. TQB2450 is a novel PD-L1 blockade developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Nanjing, China). This study aims to investigate the efficacy and safety of anlotinib plus TQB2450 as first-line therapy for patients with advanced ESCC.
Methods
Patients with previously untreated metastatic or locally advanced ESCC, whose age was between 18 and 75 years, with ECOG PS of 0 or 1 score and life expectancy of >3 months were inclusion criteria. Eligible patients were administered with anlotinib (12mg, po, d1∼14, q3w) plus TQB2450 (1200mg, iv, d1, q3w) until disease progression or unacceptable toxicity. The predefined sample size was 46. The primary endpoint was ORR, secondary endpoints included safety, PFS, DCR, DoR and OS.
Results
From Mar 2022 to Sep 2022, a total of 46 patients were enrolled. At the data cut-off date (Mar 2023), the preliminary ORR was 69.6% (95%CI: 54.2%∼82.3%), DCR was 93.5% (95%CI: 82.1%∼98.6%). At the data cut-off date, 9 pts discontinued treatment due to PD, the preliminary prognostic result exhibited that the median PFS of the 46 pts was 9.92 months (95%CI: 8.26∼11.58). Additionally, safety profile exhibited that the regimen was tolerable. The common grade ≥3 treatment-related adverse events in 46 patients were hypertension (7%), hyponatremia (4%), low white blood cell count (2%), neutrophil count decreased (2%), platelet count decreased (2%), intestinal obstruction (2%), haemoptysis (2%) and toothache (2%).
Conclusions
The preliminary results highlighted that anlotinib plus TQB2450 as a first-line therapy for advanced ESCC showed encouraging efficacy and manageable safety profile.
Clinical trial identification
NCT05038813.
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Zhengzhou University.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1479P - Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Presenter: Hugo Arasanz
Session: Poster session 21
1480P - Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Presenter: Jonas Saal
Session: Poster session 21
1481P - Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Jose Miguel Jurado García
Session: Poster session 21
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1483P - Challenge of systemic first-line treatment of elderly lung cancer patients
Presenter: Konstantinos Ferentinos
Session: Poster session 21
1484P - Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
Presenter: Louisa Hempel
Session: Poster session 21
1485P - Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 21
1486P - Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Presenter: Sarah Sharman Moser
Session: Poster session 21
1487P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Presenter: Qi-Ming Wang
Session: Poster session 21